A single-center prospective randomized positive controlled intervention trial of a pharmacological intervention strategy for gallstone prevention after bariatric surgery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400094215

Enrollment

Unknown

Registered

2024-12-18

Start date

2024-06-02

Completion date

Unknown

Last updated

2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gallstone disease

Interventions

Xiaoyan Lidan Tablets:Oral Xiaoyan Lidan Tablets at a dose of 4680mg per day in three divided doses

UDCA group:Oral ursodeoxycholic acid at a dose of 500 mg per day, divided into morning and evening.

Eligibility

Sex/Gender

All

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18 years and older who are scheduled to undergo bariatric surgery for the first time for morbidly obese treatment; 2. The patient has an intact gallbladder without abnormalities.

Exclusion criteria

Exclusion criteria: 1.Patients on other investigational drugs; 2.Patients who plan to become pregnant within 1 year of undergoing the surgery; 3.Patients with a recent diagnosis of tumor or inflammatory bowel disease.

Design outcomes

Primary

Measure	Time frame
Cholelithiasis formation rate;	—

Countries

China

Contacts

Public ContactSun Xitai

Nanjing Drum Tower Hospital

gentleyh@163.com+86 189 1295 7297

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026